Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 18 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Isosorbide-mononitrate does not offer protection against first variceal bleeding in patients with cirrhosis

In the prevention of the first variceal bleeding in cirrhotic patients with ascites, nadolol is superior to isosorbide mononitrate, finds a study in the September issue of the Journal of Hepatology.

News image

fiogf49gjkf04

Variceal bleeding is a common and often severe complication in patients with cirrhosis and portal hypertension.

Once such bleeding occurs it is a high resource-consuming event that is associated with a high mortality rate, which in the most recent series has approached 25%.

β-blockers have been shown to effectively prevent first variceal bleeding (FVB) in cirrhotic patients. However, these drugs are not effective in the treatment of all patients.

The addition of isosorbide-mononitrate (Is-Mn) to non-selective β-blockers has therefore been suggested to improve the clinical efficacy of these drugs.

This combined therapy promotes a greater reduction in portal pressure, almost double that which can be achieved with the use of β-blockers alone.

Several studies have strongly suggested that this combined therapy is the treatment of choice for the secondary prevention of variceal bleeding.

In the treatment of primary variceal bleeding, however, the evidence supporting the use of β-blockers and Is-Mn in combination is controversial.

A combined analysis of 3 separate studies, involving 522 patients, found no significant differences in the prevention of first bleeding and mortality between patients administered the combination therapy, or those given β-blockers alone.

Furthermore, in some patients with ascites, the use of β-blockers can be precluded by the high rate of contraindications and side effects.

In this situation, Is-Mn alone, with its ability to reduce portal hypertension as a long-acting vasodilator, has been put forward as an alternative to β-blockers in the prevention of FVB.

Researchers in Italy have therefore compared the efficacy and applicability of nadolol and isosorbide-mononitrate in preventing FVB in a population of cirrhotic patients at high risk of variceal bleeding with ascites, who can be frequently intolerant to β-blockers.

A total of 80 consecutive cirrhotic patients with ascites and esophageal varices (25% average risk of bleeding at 1 year) were considered.

28 of these patients were excluded from taking further part in the study due to contraindications, and the remaining 52 were randomly assigned to receive either nadolol (n = 25) or Is-Mn (n = 27).

Is-Mn - offers no protection against FVB in cirrhotic patients
Journal of Hepatology

The researchers found the frequency of contraindications was greater for β-blockers than Is-Mn (35% versus 0%).

During 21.3 ±11.6 months of follow-up, side effects forced 6 patients taking nadolol and 4 taking Is-Mn to stop treatment.

Bleeding occurred in 2 patients taking nadolol and 10 taking Is-Mn.

The probability of bleeding was significantly lower in the nadolol group whereas overall survival was similar between both groups. A total of 7 patients on Is-Mn and 8 on nadolol died.

Dr Gianmario Borroni, one of the authors of the report, commented that, perversely, in patients with ascites, Is-Mn is tolerated but ineffective while nadolol is effective but less tolerated.

In an accompanying editorial on the alternatives to non-selective β-blockers in the treatment of FVB in the same issue of the journal, Dr Juan Carlos Garcia-Pagan said that the study by Borroni et al. "clearly showed that Is-Mn does not offer any protection against first variceal bleeding in patients with cirrhosis."

J Hepatol 2002; 37(3): 315-321
16 August 2002

Go to top of page Email this page Email this page to a colleague

 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Medication nonadherence and health care costs
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Socioeconomic characteristics in diverticular disease
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Rural residence and risk of IBD
 02 November 2017 
Sexual functioning in Hep C
 01 November 2017 
Heartburn relief in adolescents with GERD
 01 November 2017 
Barriers to hepatitis C treatment
 01 November 2017 
Autoimmune pancreatitis in children
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 31 October 2017 
Endoscopic indices of disease activity for Crohn’s
 31 October 2017 
Follow-up of positive results on fecal blood tests
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's
 26 October 2017 
Conversion to open laparotomy in rectal cancer
 25 October 2017 
Conversion of colonoscopy to sigmoidoscopy
 25 October 2017 
Fecal microbiota transplantation
 25 October 2017 
Rifaximin and survival in hepatic encephalopathy
 24 October 2017 
Eosinophilic esophagitis with swallowed topical corticosteroids
 24 October 2017 
Meta-analysis in nutritiona research
 23 October 2017 
NAFLD-related hepatocellular carcinoma in liver resection
 23 October 2017 
Outcome of hepatic sarcoidosis
 20 October 2017 
Hospital readmissions reduction program
 20 October 2017 
Conversion of planned colonoscopy to sigmoidoscopy
 19 October 2017 
Fecal immunochemical tests in colorectal cancer screening
 19 October 2017 
Current management of chylous ascites

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us